More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$138255880
EPS
0.26
P/E ratio
34.5
Price to sales
1.58
Dividend yield
--
Beta
1.19707
Previous close
$8.87
Today's open
$8.43
Day's range
$7.22 - $8.69
52 week range
$4.54 - $16.37
show more
CEO
Stephen L. Silvestro
Employees
133
Headquarters
Waltham, MA
Exchange
NASDAQ Capital Market
Shares outstanding
18835951
Issue type
Common Stock
Healthcare
Healthcare Providers & Services
OptimizeRx to Participate in the 15th Annual ROTH Technology Conference
WALTHAM, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at critical decision points, today announced that management will participate in the 15th Annual ROTH Technology Conference taking place on Wednesday, November 18, 2026, in New York, NY.
GlobeNewsWire • 18 hours ago

These Analysts Cut Their Forecasts On OptimizeRx After Q3 Results
OptimizeRx Corporation (NASDAQ:OPRX) reported upbeat earnings for the third quarter, but lowered its sales guidance on Wednesday.
Benzinga • Nov 12, 2026

What OptimizeRx (OPRX) Said on Its Q3 Earnings Call
OptimizeRx NASDAQ: OPRX lowered its 2026 revenue outlook after third-quarter sales fell 17%, even as cost reductions and a favorable product mix helped the healthcare marketing technology company increase profitability.
MarketBeat • Nov 12, 2026

OptimizeRx Corporation (OPRX) Q3 2026 Earnings Call Transcript
OptimizeRx Corporation (OPRX) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 12, 2026

OptimizeRx Reports Third Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance
WALTHAM, Mass., Nov. 11, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the three months ended September 30, 2026.
GlobeNewsWire • Nov 11, 2026

OptimizeRx Corp. (OPRX) Q3 Earnings and Revenues Beat Estimates
OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.2 per share a year ago.
Zacks Investment Research • Nov 11, 2026

OptimizeRx Sets Third Quarter 2026 Conference Call for November 11, 2026 at 4:30 p.m. ET
WALTHAM, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at critical decision points, will hold a conference call on Wednesday, November 11, 2026, at 4:30 p.m.
GlobeNewsWire • Oct 28, 2026

OptimizeRx and PulsePoint Partner to Connect HCP Media Across the Funnel
Latest DSP integration expands buyer access to OptimizeRx point of care inventory through existing programmatic workflows Latest DSP integration expands buyer access to OptimizeRx point of care inventory through existing programmatic workflows
GlobeNewsWire • Oct 27, 2026

OptimizeRx Brings Net New Authenticated HCP Reach to The Trade Desk Through OpenPath
WALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at critical decision points, today announced an integration with OpenPath, The Trade Desk's supply path optimization solution, making OptimizeRx's authenticated point of care inventory available directly to advertisers using The Trade Desk's leading, data-driven demand side platform (DSP).
GlobeNewsWire • Sep 22, 2026

OptimizeRx: Gross Margin Gains And Improved Long-Term Outlook
OptimizeRx is upgraded to 'Buy' due to an improved 2027 growth outlook and an attractive valuation. Q2 2026 saw gross margin rise to 76.5%, marking five consecutive quarters of gains amid a strategic shift to higher-margin offerings. OPRX reaffirmed 2026 guidance: revenue of $95M–$100M and adjusted EBITDA of $21M–$25M.
Seeking Alpha • Sep 18, 2026

¹ Disclosures

Open an M1 investment account to buy and sell OptimizeRx Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.